Evidence map›Paper›PMID 38425206›Full record

ReviewEuropean psychiatry : the journal of the Association of European Psychiatrists2024

Baseline symptom severity and efficacy of Silexan in patients with anxiety disorders: A symptom-based, patient-level analysis of randomized, placebo-controlled trials.

Markus Dold, Hans-Jürgen Möller, Hans-Peter Volz, Erich Seifritz, Sandra Schläfke, Lucie Bartova, Siegfried Kasper

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in European psychiatry : the journal of the Association of European Psychiatrists, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. European Psychiatry: 2024 in review.European psychiatry : the journal of the Association of European Psychiatrists · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Markus DoldDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.ORCID 0000-0001-8914-2192
Hans-Jürgen MöllerDepartment of Psychiatry and Psychotherapy, Ludwig Maximilian University, Munich, Germany.
Hans-Peter VolzHospital for Psychiatry, Psychotherapy and Psychosomatic Medicine Schloss Werneck, Werneck, Germany.ORCID 0000-0001-5438-8918
Erich SeifritzDepartment of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zürich, Switzerland.
Sandra SchläfkeDr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany.
Lucie BartovaDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-1769-8025
Siegfried KasperCenter for Brain Research, Medical University of Vienna, Vienna, Austria.ORCID 0000-0001-8278-191X
Dr Willmar Schwabe (Germany) · DEMedical University of Vienna · ATBDH-Klinik Hessisch Oldendorf · DELudwig-Maximilians-Universität München · DEUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The influence of baseline severity on the efficacy of Silexan, a proprietary essential oil from

Indexed as

Anti-Anxiety AgentsLavandulaOils, VolatileAnxiety DisordersDouble-Blind MethodHumansPlant OilsRandomized Controlled Trials as TopicTreatment OutcomeAnti-Anxiety Agentslavender oilOils, VolatilePlant Oilsanxiety disordersefficacylavenderseverity of illnessSilexan

Identifiers

PMID38425206
PMCPMC10966615
OpenAlexW4392354097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.